MBX Biosciences宣布canvuparatide治疗慢性甲状旁腺功能减退症的关键3期oPTimize试验首例患者给药

----- 0001193125-26-369674.txt -----
0001193125-26-369674.txt : 20260827
0001193125-26-369674.hdr.sgml : 20260827
20260827083434
ACCESSION NUMBER: 0001193125-26-369674
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT: 20260827
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260827
DATE AS OF CHANGE: 20260827
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: MBX Biosciences, Inc.
CENTRAL INDEX KEY: 0001776111
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42272
FILM NUMBER: 261325318
BUSINESS ADDRESS:
STREET 1: 11711 N. MERIDIAN STREET
STREET 2: SUITE 300
CITY: CARMEL
STATE: IN
ZIP: 46032
BUSINESS PHONE: 3179893100
MAIL ADDRESS:
STREET 1: 11711 N. MERIDIAN STREET
STREET 2: SUITE 300
CITY: CARMEL
STATE: IN
ZIP: 46032
8-K
1
mbx-20260827.htm
8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 27, 2026
MBX Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-42272
84-1882872
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
11711 N. Meridian Street
Suite 300
Carmel
,
Indiana
46032
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
(317)
659-0200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
MBX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD Disclosure.
On August 27, 2026, MBX Biosciences, Inc. (the "Company") issued a press release (the "Press Release") titled “MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with
Hypoparathyroidism.” A copy of the Press Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing
.
Item 8.01 Other Events.
On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). A summary of the trial design is as follows:
Phase 3 oPTimize trial design
The Phase 3
oPTimize
trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-weekly canvuparatide in adults with chronic HP, followed by a 78-week open-label extension. Approximately 160 patients will be enrolled and randomized 3:1 to receive canvuparatide or placebo during the 26-week double-blind treatment period. Canvuparatide will be administered once weekly using the same device intended for commercial use.
The 26-week double-blind treatment period consists of:
•
A four-week fixed-dose period at 600 micrograms or placebo once weekly
•
An 18-week individualized dose-titration period (up to 1,600 micrograms once weekly)
•
A four-week dose-maintenance period through Week 26 without increases in study drug, active vitamin D, or calcium supplementation.
The primary endpoint will evaluate the proportion of patients achieving a composite responder endpoint at Week 26, defined as meeting all the following criteria:
•
Maintenance of normal albumin-adjusted serum calcium levels
•
Independence from active vitamin D
•
Reduction of calcium supplementation to ≤600 milligrams per day
•
No increases in study drug dose during the four weeks preceding the Week 26 assessment
Key secondary endpoints include normalization of urinary calcium excretion while maintaining normal serum calcium in patients with elevated baseline urinary calcium excretion, and improvement of physical functioning and hypocalcemia-related symptoms. The trial will also evaluate additional measures of bone mineral metabolism, kidney health, bone biomarkers, patient-reported outcomes and long-term safety.
More information on the trial can be found at
www.clinicaltrials.gov
, identifier NCT07699471.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders; the potential for canvuparatide to be a once-weekly PTH replacement therapy and standard of care; the advancement of canvuparatide toward potential registration; the design, conduct and anticipated enrollment of the Phase 3 oPTimize trial; the intended use of the commercial device in the trial; and MBX Biosciences’ uses of capital, expenses and financial results, including the anticipated cash runway timing.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities, including the risk for differences between interim data and final data from the Company’s ongoing clinical trials; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; and risks related to the competitive landscape for MBX Biosciences’ product candidates; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the three months ended March 31, 2026, as well as subsequent filings filed with the Securities and Exchange Commission (SEC), including the matters described in this Current Report on Form 8-K. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release Issued by MBX Biosciences, Inc. on August 27, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MBX BIOSCIENCES, INC.
Date:
August 27, 2026
By:
/s/ Steven L. Hoerter
President and Chief Executive Officer (Principal Executive Officer)
EX-99.1
2
mbx-ex99_1.htm
EX-99.1
EX-99.1
EXHIBIT 99.1
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Global registrational trial to enroll approximately 160 adults with HP to support once-weekly canvuparatide’s potential as a best-in-class PTH replacement therapy
CARMEL, Ind., and BURLINGTON, Mass., August 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).
“The initiation of our pivotal Phase 3 program marks an important milestone for MBX as we advance once-weekly canvuparatide toward potential registration,” said Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences. “The promising efficacy observed in the Phase 2 Avail™ trial and the sustained clinical effect demonstrated through one year of treatment reinforce our confidence in canvuparatide’s potential to become a new standard of care in the treatment of HP. We look forward to advancing the Phase 3 oPTimize trial and bringing once-weekly canvuparatide one step closer to patients living with chronic HP."
Phase 3 oPTimize Trial Design
The Phase 3 oPTimize trial (
NCT07699471
) is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-weekly canvuparatide in adults with chronic hypoparathyroidism, followed by a 78-week open-label extension. Approximately 160 patients will be enrolled and randomized 3:1 to receive canvuparatide or placebo during the 26-week double-blind treatment period. Canvuparatide will be administered once weekly using the same device intended for commercial use. More information on the Phase 3 oPTimize trial is available at
https://www.optimize-study.com/
.
The 26-week double-blind treatment period consists of:
•
A four-week fixed-dose period at 600 micrograms or placebo once weekly
•
An 18-week individualized dose-titration period (up to 1,600 micrograms once weekly)
•
A four-week dose-maintenance period through Week 26 without increases in study drug, active vitamin D, or calcium supplementation.
The primary endpoint will evaluate the proportion of patients achieving a composite responder endpoint at Week 26, defined as meeting all the following criteria:
•
Maintenance of normal albumin-adjusted serum calcium levels
•
Independence from active vitamin D
•
Reduction of calcium supplementation to ≤600 milligrams per day
•
No increases in study drug dose during the four weeks preceding the Week 26 assessment
Key secondary endpoints include normalization of urinary calcium excretion while maintaining normal serum calcium in patients with elevated baseline urinary calcium excretion, and improvement of physical functioning and hypocalcemia-related symptoms. The trial will also evaluate additional measures of bone mineral metabolism, kidney health, bone biomarkers, patient-reported outcomes and long-term safety.
The Phase 3 oPTimize trial builds on positive results from the Phase 2 Avail™ trial and ongoing open-label extension study, which demonstrated results consistent with restoration of systemic PTH activity, including normalization of serum calcium, reduction of urinary calcium excretion, restoration of bone metabolism and increase of eGFR. Together, these findings support once-weekly canvuparatide’s potential to become a best-in-class PTH replacement therapy for people living with chronic hypoparathyroidism.
About Hypoparathyroidism
Hypoparathyroidism is a rare endocrine disorder characterized by deficient or absent PTH production, resulting in hypocalcemia and disruptions in mineral homeostasis. Current first line standard-of-care treatment consists of calcium supplements and active vitamin D, which do not replace the missing hormone or restore physiologic homeostasis and may be associated with significant treatment burden and long-term complications. Chronic HP affects over 250,000 patients in the US and EU along, with an annual incidence estimated at over 7,000 patients per year.
About Once-Weekly Canvuparatide
Canvuparatide is an investigational long-acting parathyroid hormone peptide prodrug being developed as a once-weekly PTH replacement therapy for adults with hypoparathyroidism. Canvuparatide is designed to provide continuous, infusion-like exposure to active PTH through a convenient weekly subcutaneous injection. Canvuparatide has received Orphan Drug Designation from the U.S. Food and Drug Administration and Orphan Designation from the European Medicines Agency for the treatment of hypoparathyroidism.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of
novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism
in Phase 3
; and an obesity portfolio that includes MBX 4291
in Phase 1
, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at
www.mbxbio.com
and follow it on LinkedIn.
About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform
MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders; the potential for canvuparatide to be a once-weekly PTH replacement therapy and standard of care; the advancement of canvuparatide toward potential registration; the design, conduct and anticipated enrollment of the Phase 3 oPTimize trial; the intended use of the commercial device in the trial; and MBX Biosciences’ uses of capital, expenses and financial results, including the anticipated cash runway timing.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences’ expectations with
respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences’ audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended June 30, 2026, Annual Report on Form 10-K for the year ended December 31, 2025, as well as subsequent filings filed with the Securities and Exchange Commission (SEC). MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
Investor Contact:
Pete De Spain
MBX Biosciences
pdespain@mbxbio.com
GRAPHIC
3
img258572290_0.gif
GRAPHIC
begin 644 img258572290_0.gif
M1TE&.#EAL0&K /< /___P ,P 9@ F0 S _P S S,P S9@ SF0 S
MS S_P!F !F,P!F9@!FF0!FS !F_P"9 "9,P"99@"9F0"9S "9_P#, #,
M,P#,9@#,F0#,S #,_P#_ #_,P#_9@#_F0#_S #__S, #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8 &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P ,P
M,\P 9LP F
8" @(:&AHR,C).3DYF9F:"@H*:FIJRLK+.SL[FYN<# P,;&QLS,S-/3T]G9
MV>#@X.;FYNSL[//S\_GY^2'Y! $ + "Q :L 1PC_ $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI
"E=B4K-JT;N.*E0MW+42Z;\
?&ZG:$Q\M_($-M>ME@WK<3.>2E3!!TW\,3&
MJ ?3R+IZL>O4BMM6=4GZ,MF*DFW[?:C9,T;=7"_VK
*=M5]"
M#)HE$(/Y<1A>@:!U9"!@YB6(H(,,8?B>0!9.5V%J'\IGWXQ/=13>7BUV^%]W
MH(EFT(D>>N3?7R$NI.)""/+((HXT&N>B= C9.*5U&#'(UI(3!5@0D1M]=:"(
M*_Y6YE%0+N;0E88YE"9C#TI6)%LC8G1D@Q^JJ&>'#.THI$A>LBCHH(06:NBA
MB(I400X55$#0HI#FD.BDE%8:5*28,JJIHP-M.E"D!VTJJ4"-:HH0J :5RJE
MG@(@ZD&J$O_4:D&8R@HIK*:RBFI!K:HZJJ7 &IKIL(S:6NRGQ.[ZJ:BW(LOL
MJ\:NZFJRQRZ[:$*Q/OILK;12*RT R08K[KCDEFONN>BFJ^ZZ[+;K[KOPQBOO
MO/36:^^]^.:K[[[\]NOOOP!/^N95@@T\&TXR8C?24G,YE21O3S4
M%\1).Y?1SL&=YO3,0%+]=+!&=QWT
M:RWY_#++53\TMMA1.[D0VG9JO7'/&9]-F
/)7??B=-,M>$>*-YZNWI0O-S24)%VM]D"1V\6YU@0:U'D+(C<.
M>N&GE_T;ZDV3B_?KE0\,4L)S*9DZXYXK%'?2'"I^EM81L;ZYYF4A6GE!L(--
MT/$:F6[WVGU'_UC!TDNY^$
#_>R/?81@07;XTKXN#F@Y0V0>
M^;*/T/*5P(H=5! "2JW0)'N=Q%)&@DG)YY$/C]/[S"0U%DA3:FR5"1E:):'I
M(%T>#$;6W*5,;EG* BJSFZF\BRO;YDIO!C"6#*/F=M Y''4ZJ)
?_,RTWMDK+L$C&%B9![\LYU\X0GCES"3G1:K:&M=(A#LU3.
MC)03DT4#9T#'I=".&HTE!MU*;*"&S(E)DY*2M*
5&:%O8TU)$/I5,SEG]ZE%1@I*BL91(7'O65E;^]KTZC>]L?[J120ZW**.<
M;6FWMU_%,I*F$MVJPOIWU:PR5I^I?2IRJ7I4JHY5)N
?$?TG
M+8
)QE(KJ9B"3\()8-
MHN,:0JO.(R3BE']\0S0[",=\WC.1U4R0*3,:T#1^M*,AA0,36K"%9'9AII_%
M1$H;^M.@#K6H1TWJ4IOZU*A.M:I7S>I6N_K5L(ZUK&=-ZUK;^M:XSK6N=\WK
M7OOZU\ .MK"'3>QB&_O8R$ZVLI?-[&8[^]G0CK:TITUM&(7U)"V-I&VSQ]"6
MHFLX,PBWN,$B[G&7V]RU5=*YPTWN<[>[W.U^ $_ ;6YM\S9[\$YW-%N:[W?S
MN][GMJB_R9U3@(>;H]DVJ2H7CE&?MM1B8
'R.NDX1+O,$2;^=G,LYQBWN\
MX]_]N+XUTO&+?[+=*/]'-[U3SNYZKZGE,%^YREE.;YRLV]\C#_G-R[WQ==,[
MWSL/>L %XVZ?)Q#HZP[6PQ,.<88KW-ZLG+C3FR[UEM6DY-XV+M;=*?*M=]WC
MXO0ZU#DC=JD"3>8QI[G:9T[9F;L][6\_94UBWO)W0\[@ "?ZO^M>]('_?.]R
M#W"_W:TCP.-;Z55_NN*I;M)],_[Q3(\\MTE9]K&K]^N6#S'865IYLZ_VZSEG
M$N9#_\ZXKQWNJ ]\?U)_>K2[GN S\3G.52\
D#JWN>YU[H!^>,
M[6-^-\AGW/A+/[[G@1KQY#N_^
R:^[KO7@-[W_
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M2')VV'7?YH08&(A,*(B Z(+7 8.S-WL,"()S@X@C_^>(RI&(0U=7MU>)PY
7A'J.A];=> ]/. J0B$WKA_Z=%YNX
.L ==EDA[
MCBA_O"2)P!>/]FB"9U&"YK8NT*B) /F/ OF)TJAQULB-VZB-O+=UQ*60]>B*
M$'F'IC5]F%B+Z7B1%IF1'C@2Q8B,P+B,!72%-=>0(JENQ&B,)^F+X,B"*8EN
M>/6,!!F-,AF0,4F3=R42I?]8$#D)'GZX8!U76WM8?WWH@-]8+N=XE!B)CAK9
M>H 2C\.H@KIUC_;#B&V'@F$RCRNYB.[(B!Y9@3,YD-0(DV%9D##)%ZB(A)O'
M?=FHBFB9<1.)D-OGAZQX=DBYE$E9ETJY
[W
M&2U)AE,XCD@!EIQ8DXXIEH_9<388CG#YD$4I@4&YD-58> XI5&K)F9]9*'<9
M=XV(ETBY3J6)>G<'E?K&CUM)CR9I>X(#B
T4(7:/)A\_9EAY'@0/1>822E^$W)]B9E.2WG:E'B<68
MFU/_*(966(;P"'B.-)C=:(QUV)&]:1ID&9^1U'+"*9":5Y^+USQG"9K6)Y3/
MN9G2!:#5QY#=MY.!89>LQTL(6HCPB)INEX(EV)Y<^8LLY92:9Y70294*FH_,
M.(SY&#Z1*8W[]I60N5&
-)CPAIQ%:A0E&I8]\IACR1 5
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M)RNN*PNR+
TZKNO:MI*[M2?[*VMKLVE+N89[N5B;
MLHY+LN6JKYC+N <[NHB;N9^+L+XJNJ;;NJI[9"Y;MU ;M,[*NGJFLU?KNH66
CLZ@;O,([O,1;O,9[O,B;O,J[O,S;O,[[O- ;O=)K; $! #L!
end
GRAPHIC
4
img258572290_1.gif
GRAPHIC
begin 644 img258572290_1.gif
M1TE&.#EA< &$ /< /___P ,P 9@ F0 S _P S S,P S9@ SF0 S
MS S_P!F !F,P!F9@!FF0!FS !F_P"9 "9,P"99@"9F0"9S "9_P#, #,
M,P#,9@#,F0#,S #,_P#_ #_,P#_9@#_F0#_S #__S, #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8 &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P ,P
M,\P 9LP F
8" @(:&AHR,C).3DYF9F:"@H*:FIJRLK+.SL[FYN<# P,;&QLS,S-/3T]G9
MV>#@X.;FYNSL[//S\_GY^2'Y! $ + !P 80 1PC_ $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI
-H,*==FSJ,ZA&'\J?9#1J-.E/I%*G4IUJ*&K
M6+-JW
S6N7KE^S
M=O7&%7P6;N' ;P/7-
O6L!.H5GU0]FO;L5GCWJV[]U&!#WS#/HWP0>[?Q ^"'IS8,-J#
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M66PMYFUBGW)&V&+GFAON9^A^VY9"D(U7"*A\1O@:?[G]%ZV@D48\Z<3$"D
59@BSY%$&&\,/D]CQRW!2M')OT.I&*FO\I0J>
MR.5R"QU6-V;*,LX6+^G0S#M5!_-U$B%-YX\+&[T@3D,/E"#14;
C9]Q67_NO?3$9FM
MIXA9OX@WX 7]?3;=;..VHN(9P5FTE9"WY[1%_XY<<^/8%3TM<(J?%^%_#A/8
MD>#U%>[RX2FR'J;KU-;]>=H#!N
>&"]>Z\Z]#;SS,N#=8-_),7FX2R#;>2KR!U_<^/
2!*A0*2(1
MH:Y0N!V<9*,G*GF7#HVU$9Q4,"HYDF%8_VA(Q(CLT%B,&(^S@-:T,:GP:T4,
M8+BF.++0^.MWS^G(#I7(1(O\A(11)-6WSJ6NM?3EC&9,([C6:)DVHI&-;W2C
M&N7R+3<^!%E+G%L83=7&"NVE7F843)0TUA)S"1*0B+1B&N.BR#6JY5L+P4H>
MX:7'/8ZE6YB,B["B1,
E*-=2185I8X*DP12G(Y"Z)MUJ2V5
6M$YF63(XXY=B)
M
DE)%
M(4XBW/JE(A'"B*:)])I 15-##@I1FGKSIM639D+'1E3\'!4 1ZVF-+<65&5Z
MLTL/Y6=!E"K5KEZ540R-JEB7JA![4;0T8/NHI2AW2J+13J1:8Q1
#.WEZ##7=-"Q>_:I+Q>8-L7@M'D7@2*,6
E95:TZ5*FI:RK=@%K8L0I(K&G+*ED5@LNPCO:9[U'MC#YID<7_CI2F
M?Z4K06SKV)\J3".\7>U6!PNQF1UMK]G4JSLE2SFXRHQAB3VM8EL;3W8Z=[(
M)61M91O:AQ9(M<+U"%'GU-UD.O6:24+OD%#K4NX:%:C"#6MGP5O-B8"RHL#M
MK4^).S6[LB2X=S5L<1>7*.0>=[G)W:UCL0I7SPZ5ORAQI$ Y E[A>E6WNP5O
M2\:+X0>+]DSJ+1)[11SB[TZ5<0=E;N?<&Q+%H"2Q"6LH09 )8Q7W%\8;UF_3
M(*Q
UZRWQ@E@\+"K/]\3?E:^:K9K*R:!R_Z$7BZ@$,WJH\,KYSGC.LY[W
MS.<^^_G/@ ZTH =-Z$(;^M"(3K2B%\WH1COZT9".M*0G3>F+5- !#\ TIL%8
MZ4ZWIX+&N72F1PUJ3YMZN*1.]:93;>=3'UK3%!PUK$4]ZU:[>M#Y$S6H8[WJ
M4(^ZI;>NB:IY/>I
.$^R3B3O>WGWUMB%0[?^_F=%6<+>ICS[HC\79VMZG-[G8;
M!-/
U,+SQ5*(,,LY9ULH)]_#$3>7C#$Q+N=6O[
MY0",N,A)/O**$YWH'E^BR3G"\J;W&^C!$KE6*OX8JA=49KN^8*FA3I-'ULOK
M8#\&,,1.]K&;O>QH/[O9O\YVL&O775EA1"J8A?0DCKR27!=+P/!2=K:(O>V
M!WO@!R_XPA/^[VL/F#$@,G6:2]+N5\E[UQ&?]K8C_NN7?R3E-<]YOQ<^\YZW
M_.='CWFU?YT6#5'6W4]F,+Q+'B1A3SS@@_%WVAO^]I
]L$'?N4CR?K'1Q[Y$&'^[R=<*K![9_O1+SW_
M.
&=A'R&EI[P $[]YT;M?[<<0I;/D[GI$'QMST!?*_<4B_O _WV0S=WW$
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M=L*(-V@1HH"'"!%Q="B&>)*"/MB(?CB*@/B)
-Z@A8
MZ0B!-D6 V#B(1.AY(&*"P^B*"26.\VB.R2B0XVB,^,.#['B-G5B0 FF+#IF0
M!MF/#@B/!-D0T1
F1R#B-(;F))]F,
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M.9_=Z:&]N:#JV9D3BHPD6&[*EFQQ)5@DR1!;EQ :,Y@O=ID,BI^G Z+4J9\
M&J)7V:$G2:.52:-=")M\.9X@8:,YNJ#\&:'K^8E NI>7R8>J"(*O6*2)::'H
M*9XZRJ!)VJ/G:8Y/^J74.!G%:8 ).1$H>FP-T"-S2)BLR:0D:IU.^J0V28NG
?R*6"F*=ZNJ=\VJ=^^J> &JB".JB$6JB&>JAZ%A .P$!
end
EX-101.SCH
5
mbx-20260827.xsd
XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
100000 - Document - Document And Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
Cover [Abstract]
Amendment Flag
City Area Code
Document Period End Date
Document Type
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, Postal Zip Code
Entity Address, State or Province
Entity Central Index Key
Entity Emerging Growth Company
Entity Ex Transition Period
Entity File Number
Entity Incorporation, State or Country Code
Entity Information, Former Legal or Registered Name
Entity Registrant Name
Entity Tax Identification Number
Local Phone Number
Pre-commencement Issuer Tender Offer
Pre-commencement Tender Offer
Title of 12(b) Security
Security Exchange Name
Soliciting Material
Trading Symbol
Written Communications
XML
7
R1.htm
IDEA: XBRL DOCUMENT
Document And Entity Information
Aug. 27, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 27, 2026
Entity Registrant Name
MBX Biosciences, Inc.
Entity Central Index Key
0001776111
Entity Emerging Growth Company
true
Entity File Number
001-42272
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
84-1882872
Entity Address, Address Line One
11711 N. Meridian Street
Entity Address, Address Line Two
Suite 300
Entity Address, City or Town
Carmel
Entity Address, State or Province
IN
Entity Address, Postal Zip Code
46032
City Area Code
(317)
Local Phone Number
659-0200
Entity Information, Former Legal or Registered Name
Not Applicable
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Ex Transition Period
false
Title of 12(b) Security
Common Stock, $0.0001 par value per share
Trading Symbol
MBX
Security Exchange Name
NASDAQ
XML
8
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
9
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
11
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
25
1
false
0
0
false
0
false
false
R1.htm
100000 - Document - Document And Entity Information
Sheet
http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation
Document And Entity Information
Cover
1
false
false
All Reports
Book
All Reports
mbx-20260827.htm
mbx-20260827.xsd
http://xbrl.sec.gov/dei/2026
false
false
JSON
13
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"mbx-20260827.htm": {
"nsprefix": "mbx",
"nsuri": "http://www.mbxbio.com/20260827",
"dts": {
"inline": {
"local": [
"mbx-20260827.htm"
]
},
"schema": {
"local": [
"mbx-20260827.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
"https://xbrl.sec.gov/country/2026/country-2026.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
"https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
]
}
},
"keyStandard": 25,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2026": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 26,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 25
},
"report": {
"R1": {
"role": "http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation",
"longName": "100000 - Document - Document And Entity Information",
"shortName": "Document And Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "C_3a824e15-33b8-4de9-b71b-3d78fd0718f7",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "mbx-20260827.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "C_3a824e15-33b8-4de9-b71b-3d78fd0718f7",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "mbx-20260827.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Ex Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r7"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInformationFormerLegalOrRegisteredName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityInformationFormerLegalOrRegisteredName",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Information, Former Legal or Registered Name",
"documentation": "Former Legal or Registered Name of an entity"
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://www.mbxbio.com/20260827/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
}
}
}
ZIP
14
0001193125-26-369674-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001193125-26-369674-xbrl.zip
M4$L#!!0 ( %!D&UWVI"Y$&QX (+O 0 ;6)X+3(P,C8P.#(W+FAT
M;>T]:U?C.++?]U=HF3L[]+E1\-M)Z.X]#- SW.FF66#.SKE?]LBV3+0XME>V
M@
@ V3/F6UBRWJ4ZJVJTON_7XT2
??AIYV3WX."GOW_\R_N_4DKV/AT
7G:C6*1%EE0EC%5TPVRT12BM
M.]^5G.%SLL=*3@:687G4Z%'+/S5Z ]L:.'[7]@S_?PUC8!BMS[)\+,79L"2;
MX3N"7\'8:
EGXYU;2<
MV]353
PO@6,+2>-,>('_^C>;X.F#%I/G5C?93Z\.W35-QM:A?
M$Z>!6XX[WC1/L_00=EZ*[V0K5*RM(@S.5+HB.MT
M$1%ML]7/_+5]JQ/+HH9%S
O#1LFORBV%
MM5O8Z5;=Z_L@B\:D*,<)_["1LPB)?M#+K[9'3)Z)=,"J,ONK&.69!(B7VW\"
M["-^-3"VZ24/SD5)L5]:B#\Y9=&_JZ(
%0*7/9 \8<@IMC?4;"-Q
MT0P6B2)/V!C1!=^^%U<#G!.7^D\113Q5?U[C$Q'1AXU/_^JY<>0'3DQ=WS"H
MXYL!#6+/IP[S;>8:GLO]>(.D;(2C<#'8 384(2OZE+"S&B17Y3&/ 5C_LEG/
M
I$O$\#[-&._%X<&;[9BV$;8I84_/W6U&SF3XZY0> '/* \M!WJ
MA+%'8;XF#7C4\U@8!(%KM">WG\)>CG=A=I(E!PC
G:O
MB@C02?7>[E+]++)*JE^*D0WJ!2DHW75!]:=<@:CY)2+\'0LNB9HUGTO-NP>_
M30-D]N./S:/IWG. 5Q8UOX#-R!*ET<=K8=1\=_UN,LUH0=/F3?.[&61K"C0-
M'"> VVJ1Q!90SBP%-<1H;8]$2H<
=,NR"1,DY99/K"ZEIN7),JJ(.'D!T/];SN&KA6; /Z0ES5W
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M'>+EP $AN"R
=6?*#58C;W"=#*T;B>46R?P9&2R;*KX
M]/7X"YF'X?<8;6.^JF$%9@Q2U*'<-D$/BOLN[?L^IV9D!)S%7NB&QH,TB99Z
MTEAQ2IM<4<:C-.(:OV;UGOKQT%K3Z1/(L_Z*";/EL7T07,?[AZ?D>/_HZ_'I
MDX+%@]8O!S!'E2PJ, 5)F9$3'BI_C6F33!+3W8S>D2PFY9#CJTJ"P@BC[%^%
M0Y:>
%T &WP+05C,:M*99%NZYF!J=D%
M&JK; X@2EA=\4/"<2="WM
;2LK&C\".__&*+4JKM!B[E9=PHQI(#D['ZC_I_A@#B^X,;':0M?,
MJ6N8J.K7CQ0[,^#!!9>E"%E2=P5-)VT:0FQ]IED1/MFX$V[?CR5.\3NC:_=[
M/SXAKM\)@95S$=#PF*-3@VPVOSD#6XP7)>$7Z+64ZC6/W@VFI/=\21QRPXYZ
MKD]=!N+8<8P^[5NL#S\=,_9YS&*WMRQ)?*2,QWUM4FX0[6'ZL"&NRD$$3^@(
M1AGB9S1B8SJ&95&>/BN$=ZJS"N!H^1WEC;U--@-/W2JC&7*"/Y#H'R2U[VMB
MO3VY_:9L[F7K*-=#6<[#%'
$+F.$_@]M_=H
MQ5W[%8_YF2C0$UT>PINEZA2W+O[N^_KEYS_(SR(K0J$
8(2>Q9S8Z2])'(-
I(^*0$
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MN>F%8+
HYI^J9)#KOD
M"RP_$C#L22DY+Y=SL/*TQG48]BR;]ZCG^AYUK-BBC$6
IXYC<=H+ I_&EAO%7F"'AK.D@XYZ:Y17Z:L\DMF%4/EZJW3"<9"B4&1O
MT+]]OY/F[VP"Z 6L!-SNPOX\-PAMQ_"HQ6*@L8 YM!^&(>@O#G
)S$I#C&?;Z/.!U^DAKY,+ HB,)O%OD+"'[5SRL,/>/?(UC
M$?)B%9W3+U8E7?OT'X&OP/\(,L!;'/
#^&C^E13A?@F%<*'[, &*=H=/,9JNM/,[F C6=RQ
M I.!4>0S#W0QQZ$]Q^ T<,*X!R8MF*_LL?H;6JRXZF?7V#9MTW_W!";KLH ?
M19X5,\.AEFVA
(B]\ACL9S^]2P[N?M
M6PNOM?!ZI<+KGK:U;_5"-W \ZL;(FUG?ID'D.]0/8M_WX[X?><&R G4GE9L^
MP1]
Y$VD<9B79R?,$]@[P?749R,JGS>@-)8
M=8,AA\2CE>]E@(VV4:56\4KN,%:G2
T L\D[+8C$'QC4(L&.>!9(OBP#!MJ^\Z
MCY5L_Y2B!/ABF&F5UK&.Q
Z0< QN]FEC/489=P);;
O8%&"IPU62-
MR*V@D@ETR*@&STTL-AU&3:N%R%-U6B9H[( AH5J^04QVN!^%;AA2RW8LZO@Q
MHT&/,]HWO-A&4\3GC^;*1Y(C1\;$=U5G"X6^_!K'6(1QC=&3JD/0>]@"TZT\
MVG0B:FT&[^Z&W[KM&\1PU[-"T^Z9U/-#M*A=/*T&< 3<".Q>8/J6'RT9PP^*
MHN)RC>=+PG,;1"S6/;\+GM=M9_!\Z07-^L]0T&R)PO):?Y,3[\X4H"=ESA1#
MJ6TH .[@1?@I[8?4(WA(M033?::!G-L'>K%EV6;=/=;$W?.]7;+/X^54^7BG
M6-U>UV0+A[I2]3-&3"S> O)#K/YGV.N8O35RWQ^Y3R7#1>K:V.,1?+WYK"%4
M:\Q>8_83LNW#NA*9XMJ\T4)!<8+1X,FU=O5=,S)>6V#B@J-2T_;Z1L I9UB?
MQC,9[3L]1EW/#)TP[@=V_.B*I+7F/#:M0$GL!V+
!W(\&W6*WH-#'0EB2@.S-B,/4Z]@+O4,4-&>R9CE/5\
MN]\+_+AO6X\EHEHGT.K 4U+0EY__6-/&FC:611N68_3]ONM1TW,MZC#+H@$>
M]<218_N
)L@3'I;D
M"Y/G=TJH?EPLSJWE^^]) -_+NXD9=Z$*@!B34$5&P,3/03WDJNC43-B"* A,
MF0,PS_ DZTQFE^40':(YAC*P@D0\%JFN<*O/90UWSO4#U[<.V&03:=??QK!D
MN[^MCFB;;V T0+(<2^1B5)!VKEH!M>YXH\%LW^AOO?Z\U7MWE?S-4X$63WOA
MQRHAXOX"I+KEGAZ
C[*8J;(26+$@!M/$ZO4,-W)=*W@T.]2A
MB
W'S+
MPA"KS&)CO#
Z=^^V6]E>3.3M0
["R]&J!(=&_MICUQ?67Y]P\34[7#/9(1^+[A\3
@3Y>5" O&(@.S P'U.(,A)5N=J2>'>MGT%A=4!T1U(8M8WMF +*3IB"1
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MA\
S]4-0_Q*R0',1^$EP@W,$!B[T!8;ZS*769\(I?2:N
M";$$,Z-40:$P=#B4&?1$AC?D.=G\]>A=%Z1Y48T _A.!KD>,> '05[[5HLX#
M*P9KN?QB\?N!
>P/2"3'4F@?=R/"RNHG%;#BC?
M+U978^%8*WPLYJ7BXHM%!*IYUR;O1#C\>M2I>;S6"QGQ>ZH#DN4\I0D+>*(=
MS9@"W,7R C*[$I@S!D, >31R#?L%K1,T3I[6$\>I7:^4V -E 4H>
]2LO3
Q/$ZR/@"$U8*JBZ;_ <+2(
M7PBE@M;V0.T['W&I7.-5P==6Z1M@=W?"-3Q[* "GT/*:THE:+EB8](@FT(CR
M1&7HJ(GG+2]LNQJ$W;5M^\<9I_5TCMA
]-9BZ6>4HXLW.++Y>
M(^F[-9:NL?3IN*?"2SP$A7<,L:[&S!+TW>IL2/ X"$2]4H*S"KTQH<3CBT*Y
M()6F'
7L#%D2BFI$BBK/-78J]._.P^FUGO@Z]<1<
M"N4S V,ASP#/M+U1FV
=200C*\B(
8US
M:YQ;+LX=\Z@*&R&^0/-#:P?6U3.<;6WR)+"!RN3!;,.(C=>\<(V72\;+PVR1
MU:*LG[;_'.TB97=C,#=2\:,P@P$%>%,K!.1=3UT;,ZS-B?N,8CP._H[89
M4S2!5[6J)_Z
E"S(
M@%^/.N1<1"F
>-A^>7G9;>*3
MU+R+[EEVL8)%\CI$8"5&$0LLX[Y[:OA>O^_XYIK*EK-6E6Z\)$)[\O)]GS)Y
MR4!1_)QEYR@HU)6C*$J*%P*AYPC"_F9@-:DSB8HF6R.N09K4("TF(&U2!5#.
M"\WA0)JF=3AD$RMM^3NWY&&CC)RT-O?O'%JM*@M=QRAKF8]VPF3N#/@"7E98
M\DXSV?I- +H(O[CQ&!
D-YYEN'O A6^\D*#IWQP,5*A_SYE#,9RW#C".SOB-MI?8M'FF0H\$X"*3
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MK&03\9CHG_7FW(1REIYE*EQA*L6I5EYF&[<._!0
0T##9B)SH *QOR/-,S5UO#H+KC 2MA]S(=$
M4)U)Y6'$@'BN5-=S/L8CHB)+4PZ;V,)2K3//@\@B89/R.FH=)""J;4KW:GDS
MXRJ-E!JI=$4-/-!I>
O)H=J)54Q@X1SSU=H45 %KD#75WI@76&CP
MH2B&C=.X[;]>L*^XAPE6X:GTG&'K8)?ACU(+NT(KEG.W$>?*2Z&.J\&*BPK0
M+W7*WH+!;B+?-EJTEQQ=UH5.#*Z' GT:[() 5T2H;;1CI-M:YYC8;_!ZP6@[
M:8J+FC'Z30.OFJO3"L>
@D&&:/@_8?P/BVJ=(@W0[Y1P54R24PX)M]_.,Z
M-7$H.2
I[U&Q&3@C8B6.B48L1]S2M3QP8PC "$_<09@
M%5BA#%&R>;*_^VZ6JX$0@
"*)S6:\5N5JSV9C2K]@%I[._=;
MB3:IDXH2=MFI)9""5!TC5]-.0_EX#D*&3 8P=JS_NWWUM7%W) 4>*+6QXC/\
M4V_%,4>O^[6?J._>.ZO;>U5)W7U,ZOXT$2
95O\&2J@J)ZF^/.'N.-V4A#G,INCZ>4LSOPU0
M[RGM*L=>7O5-#JN\FW??+:R1]$8H@A&P0V(07L$5Y5?]_K_,[K <+09N'#\U
MJ4Q743O0%?1 :9Y?<2^[48?FFI>Q-9&M,)&9AO-&:.S)0+B;P>+)$0/#]@#]
MCW4.P!XZ'3]A).(F^B:BJ/83U+;A@3H!('_\?/R91!F8M-#9_"NU'E1Y_[4H
M^.O#G1=]N-/OVF[^HBY5/?CE<.?T]^/]DR<\&;\)E55R-1RUZJI/CH-D[8FY
M:\#3G'KQ4:7*_U2%*D
7MZ[YZ1K+UT!; VT-
MM-?H0WPR.?>\'K ]L(P&+P"[5QN*,Q[T-3P?"<^?QX/'!+$_( []:7=I^M(T
M0U^:IL]U7N<&;A5;Y*3$,##RN4M^S3@&]*WEP0N2TVN@K8'V)H'6]>_%5Y=[
M('#G WZ5HZJ"*W>'@L=D7R6*X.'E5RSDSR79/)(BQ>R5Y.;+]6GEVSNM?+\5
M9-'XXU_>;PW+4?+QOU!+ P04 " !09!M=@35]*/L( !+:0 $ &UB
M>"TR,#(V,#@R-RYX
DE,>(47M(,QM(FB%.L
MV# 4LD0[1&72HZ3$^?
\B#PAZ]-/\ZD+'B#U
M$,&]5J=MM #$-G$0GO1:WX9:?W@^&+0^G?UR^JNF@8O+P5?P%3Z"ONVC!WB!
M/-LE7D A>#W\\@9\__WV"@SM>SBUP 6Q@RG$/M# O>_/NKK^^/C8=L8(>\0-
M?);.:]MDJ@--B\#/*;3X=7!A^1!T3
$3N$38PC:R7#"46=^" ;;;H.^ZX)87
M\\ M]"!]@$X[!)U[3M<+1?@6G4#_JS6%WLRR8:^5DC(=S4>(" T\J7%L?FP!
MR_
@''5N#ZO5: _PLL%XT1=-CC=2%_+IF U&U6']CK0AQ,S3C=
M?$3=-J$3GLC0X=R'V$,C%VH\#%+QU#S-Y)47%F?
61Z4X8&G32QK%I<86]Y(1$
Q!
MNSTA#SJ[D0GD-QU?]7",]WIX,QV*2@BSQNBS]A$3GB\(C!Y'Y^3D1!=W6V>_
M "#:")K."/5!V%2NB"VJH209_TV3&35^2>N8VE&GS
G,T0'I/P"KO&:ZA+B0OOGF80\ _?;@?+Q@/=M^8$D^F3
MS@OH
&_%'!@9"-)"".]7S(#GXP(/.-3X3GV>4C?$X?')7[$)4. HI*6A;KAVX
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MD;C(9F]0//G"AGN*+%=%<#&H)GKL!<__"C)\FHZ(BEGV?DVD_F*5Y4/,VWV
MHX'/4Y!3QZE(\C+<_6:?^)]\(-:^#;/>"9OMDH J9\09'^.'.XJ?TTKN#<=I
MG0D,\(]$^3>RQ<3=E^:;L3C6Y!MC Y2)=NT^;'NP^6F*<< '*1*LDHW9$W6
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M**L"074IR7MA:_(790$9@X[Y>O0&2-0ZF*=MLC792R@@L2H?G!8MM'6IQT!
M(E7).V.PK=M60@P0@E3)5NFXK
=8!U7ECB=)==$+;)*J:A]4_%#S/F"31$MW
M1TG&Q6;@-E!/[YG*,X[MOR:)+MU))5F7&X';*,%<58*Y71(6=UTI!>1,OZVA
MK]R+I52P:/AMC8B"'5I*&2JOKWDA!?NVL@I4[E[SU$MW
P.+.KRSQG)/7/.&5]H-E-2PW]K9!UG-VB>7UK>SK-2]4O7
Z53UR3A57>?20$KN79;)&AU*=LDHFBGFJ2N
MM.:V@;!J_UJ>]((KURCQPEUM,6VU']
5>-\EWT8=KDFKI#CA)N=B,2Y\[
M3/EI;,7Y,W\B,7]FM,C'>]G3EM$YQGSRK ]Y.,YX.,YX.,Y8+:7#<<9:R!Z.
M,QZ.,QZ.,U9"^'"<\06H'8XS'HXS'HXSJD(.QQD/QQD/QQD/QQDW(/7BQQG3
MMLF+N%$SBS(\S;Y';CQ]6G$O5,Z@()3UYUZK8Q@=@_]/C3,VS>)MM==BB[3
M8V3(C--6-XEM$I8U.6)=G:,=UU7@E"059^Z)P-!E2709.ZZKQ*I)1)[LJ4@S
M([*S1R+3UE RRNQ58\V92HG*71]JRKVH1.>NOPL+#*RD1[[;"X$%YE
O8SN-N
MDGH=][3?[@%)4$1-$ER E*S^^CLS !]Z.?;&:11'>TXW%A\ 9C!OS R/_N%Y
M[/3EF_?L."CD1)Q*$R3*E%JPQQ_>/6&O+]^]9:
92!(Q8R]EQK- \H1]J.;L
ML#=9T&7'2<(N\#7#+H01>B+"+H[Y_5%
'[VAW=X
MV.T?/;4_X8&G[HDC7X4S9HI9(GYYE/,PE-EX^"R_'J5
]D;>5/A7LO *<5UX1OXE/![^69IBV._U?ASERDA<\5"+A".6
M1X]H.:&<+$SF%2H?]KI[,JL''XQ2F7FQ0 B'?;BQ/)JOKG%27*RO="BT!U=@
MCJ.\&CY2F5T7+"@O'#AVLA'=BW@JD]GP4J;"L/=BRBY4RK/J05\5A4KA68*/
M)W(,L^."J@<2$15PV_VB6_ 35H"#5XL(5*+T\(<>_6\TC64A/)/S0 QS+;RI
MYKE=R]3"ZJLD'"TL_*:UTKTKH3/$0Z8R08B;RK"(AQ'L30#W@8AA56=_O'[S
MXLTELU2 [ST_>IK#?[ A]<8$"3?FET
N1:N<>+.#P6 -'W0%S/_W0W^^-VCC[_"0&(,ITS(P.?GD$?PSVGNT=
M# :'O?_K=<
L1X4JR^4>&$X!CL#H"/'1L=[N?7]TR=GXK9[[[[KD+K:FC[
MZZ#MKX*VM]M >["S>=#^723T\)EDPR!L*X1^M]\[^'%1AK> [N]T^WL?$>LW
M@![ :H2^9]+>_43
3Y&1CPTZC0KJ6_'F(:;RB!0F1P
M!QRLI:J"J"H4!M;._%(FH6%@J5OS92+<"P-V/.$R 4SN[8R8%H:(C&
X^?>"/%6\)X<7[P[>XNAB+#;(0'YXK>+MV_>O[K\]7V'O0,Z@,O'Y;@$
MU3\XZ-BPQN-7;W]]<<;>G_W^X?
Q!;O!!3<>O^
#)?)T.JU6.
M96\QX4D)(V7C]3R[&H(@U@I&8O&2X<0>OSY_TMUD(W[+J7>%%Z5V,+J,T6X&
M8\>&*($*5*F7: W4Q%CSE %(5VCXL#KLQV!VD/,P%=$4\BU0[Q28()QP(+\;
M:+!04Z[#EM9H:ZN.76 X8H;+D'TH@$?9:R4T2/$..XFY!#;/B-5.8BDB=G8M
M@I)LME^C2 9"(RP+8J3+VF #4"EP./")P#=X,&/*MR%3Y#EDCU7FG^4RG!B?
M,"#*, @6-FP(HXF@ *F2JHS (4[7JAS':"
A_5@?^5HMYPB2Z4V-RZ3HL
M!0]-6G>FPS0(8X6X#3M@+99^(CP?4 *_R-/R%8V#SAXH(5.4X:QM'Z*0KW4?
MBG7#(U',R I8*]=!G;2]Q/5&8P
HTE3C&P[Z&/P*24H<@ SA
M43200%&G0M/1+3@D7?9.D8:&6ZFSP+*;="]2 MHB%'0"YV'S60G/R(T[)%?@
M2"$P'E$BG9)_>?;:NC4/3.W
1@RFE53TS,8/='%
MB/;0PQG-T ?I@_)@:;<; -QDGW7[[Y+5L-/=W3TX[!_V=_?ZO?V=PX,?1U.E
M0\^'G;\:7@F1PS*3&CDR0_@\PM$-2'&>\F!0,U$K3V5^K"]+^<>@7DIM*3^2
MUR+T,'I443NHBOU>#YSUP'KRIJT76RJL)D-,_G#_OR7'+3G>G1PSUG?V'HA?
M
CC,D<;KM]9)-.&-I^P5=0YEZ:TD(
8ILDHVJVB*\LT6LLQ6[@@8=9N2?D:D?I?LLX]L_[.%W?_Y!.;Q
MM?RY8WAF/ -[%FVV%?(9D?'I-EA-L[%>D)M.#!"S4X+E:/X&T)R]G/.QL++$
MXQ%X(D.>3/G,/(1
OWO,E;QA*^\M2W*K;K?J]I.L/U*P2(-PCXY@G(JM
MSB P=PJ<) K?J+( _1P D@R@6F8N1A3J
E<2UCC#(^W
[\L [;
M\2"6@LYY.)W#H[ 3F#V5*PPW-2."<^)HLL-"$=%I&C
B7<$\R(
M,2O]K2T1;HGPSD3X!@1^CH<@2(615NF2;;$EM2VIW0NI78BP#"I;9(VQBI$F
M!&>POSNR\:8$-H[B34!2#)/TMO2XI
\L2H
MQL?$"*:K8$B!CTIP(7$N'S,,4PRMT0V;;XUI)U
!)$7?L<[Y4F+Q*
M:=@.9%@&NJV8PU$6F$!I2WH2A=%2H5.7#;/-#WA +'9#6MJ*ZJ^JTHLLUH_G
M P/A*,J)79'@9.5^!QDSB.=S@ZM97$:"H!@+\*+&O&I=,[N9P;U4!E1)0^:S
M+&! *QP:#F^)ASE>[\!X+
F->R6
ENN=1J.ZAU
\;&/D>U;
M5@!O-_VKE.7+NVL39346/3356%7]%<@">#C P/%?-B458\T!55R!\."^P;]0
MOH!%XR1EQPEGE"=@*[6-&%LY)HTN<^J_@_
;,%V
MPH!_ D_:?DCLI"[R8)S*8P# ">S)8*_7 5IIK%!7K/+;!QKO[#
.W:U&,Y?P>O5,*M&."LU(!?NOA,A
MZ/X,6]*,08_,5E=$;]V&!\W&5F(O% E_.^ ?^7JI01-9T'?OH]"9:Z* 7-@4
M.K4B$A]OK8!Q1QJ>6AX LVHI"@Q4G)^=NX +2, "ZZ4Z_V4?!AMM/'$0(
K?*[FLH ] LL0G'/;,N>C
MDMG%;%TC#3 B)P!/:!MH +2B ,,4;&SN)]+$<+$Y(HLHL#$N ;\*N_I@,?$$
MJZ7;(8LR@SEAWI!46B9$Z$Y\<.Q6])D.BD"74."ZQ.8H8EYIM$+6E;IP9W1F
MH?KX,>K70;]W^.3.+7
E
M>G]P0W8'A_VO";\;T(3 GO8B\O8.]O?J'_O]9STZ10;#H^I_T[($.[894&([
MPC7'N$W_K49$+)EEUA2$P4_ %!4)=163/+.1UQ
1&Y9VWG;+:DSNK=?NY\^D>UQ[;$W;N
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M:,\"#)%G+O[K=AR54HX^
*VS@:LP9@2UT=.@C"8
M""3^4]+4"H]5MZKN 4F3E[8-HO=6J2LDQ0_ 9O;0?;O+#V>7+U%^P\ &SYVL
M9^!"-Z9N#NH:8GJ)HP134T+=E!3%C$M52 6G+%>0QA]L])4-#HZIP2?
K
MYQD(6 F26C0]5*M[OD@DZ++E&^[H;^6=,@F7+U=I%RON@'(,BN7KM@W:\O64
MSY8O@@[,5ERM0C0K;FD,ZZR8%I3'GRO78^+5D%GAOWQ]BH_75YVVE G7J#J0
MH$C_V(:KE1(#?1OBBJ,96T]4'?R,34Q:"M-WL-QU_<,5M;HTRVIX2GA$,B"*
M,.*F$5PHI,-\,.UQO3@KV16TY$X%#R8+D3U K0/KU[48P\#(:(LG9Y6/P"P)
M.(UNC:&1;6?(=NQO9]:Q^2U8'Y92YB57%KZ/H;5L.O[P)H1ZNIK+1Y
MN"ZT4747K)L/NJ CO5>%;59M6FF$RSK+\7,#1 8B,\[LBNHOSKETY;;51LAI
M 1)P$S-=9E,^0T-N:RD]+!WZ
.A\TI7$O:/C;F!(G6P=1\;7N?UF3<
M4#;RI:S32$RA@BL\@2A%E[T$5T3IN>D#CHP'U\N&*7#EX(%%(.!0.2)>874N
M^P2KO1SXN.06OSB)/'10VV,BY"O5]B\;),)L@FNT!!:^7N#* @!1H[7(X+Y,
M,$".GP&AGNFB.FZW!0GC68NSE5_5#^%"T/N1KHO#TEF+J9("[-8Z'PX%.HB*
M"*.L6.:WL)UM4-LQ9/+T5@24YR!
*M-X46!:
1&VA(8#U6>_79+$Z:/RBPD%6P3J E]8!"(
M0JS9DQ5HX
WZNG4[B[N88(BD;((>,_RCL.;_JHFJ4PI1V#HD,(9#
M WJY^<;"JIF6B6]4JV[85F!HV"KJ]]"@4Y$Q-H=E$G&8 ,YA7<+^G+8DWJV,
M/O2/-N"08IL_\R"2+K;Y,P]F*[?Y,[?"(';)
K(/?/$7=OSS(O^I!;H)R+H<"#35W!!')
MA IL\6C$U6
1
M$E?5@!$ARG$H^)4SVJL@:E["4P'Y-3-6YM9@IJ2LB;21,31MLYOB8%5H"Z"!
MK10RL^,3==&K#A+W/;0Y>P-+(.HG;-1H8F-KM<5+#P52!V6*MBY";!LED!^%
M!0OP1[V:.@$%XR"!R M&E0K <-J>-"9\VG%N"F'*-<)S5EUEE&(+ 19S#6J!
M-OM6T%
S&T=_2MK I,@)SHC+".#A_N;6,L#T@!+#)G607B;-BO\F4I
M:(]_HV6.7/&&JI" TBY(5Y(M7N4Y86H_GE:0/B >IU/,6NHS6)'EX[DODMA,
M'VU]OUE=6H^SN4'09VZDA+$R E9 ?A4.\?*T"Y0:*(H#)]2UP"X3)!J%X5&
MRL))0^>__GP3-!W['1KGS ("FNZ0\T/,G?6 / #95XG.CI-:],4UD#@8,\"\
M4[R!(1;7+
FA9]V>NV6[1^@A*]M
MBJV0WZ3=OA]XS_%LXA2D? ZNU+<#]C=;PIR'PN!6_W.C:B.^48G2#D;WN_W>
MP8^+X>46T/V=;G_O(Q'G>P;];PMP;T^7OJ8CB<]SNG3TU%?A[/GW1T_C(DV>
M_S]02P$"% ,4 " !09!M=]J0N1!L> ""[P $ @ $
M ;6)X+3(P,C8P.#(W+FAT;5!+ 0(4 Q0 ( %!D&UV!-7TH^P@ $MI
M 0 " 4D> !M8G@M,C R-C X,C
'-D4$L! A0#%
M @ 4&0;76A:#A2>%@ 6Y0 X ( !
"UE>#DY
<7S$N:'1M4$L%!@ # , N #P^ $!
end
XML
15
mbx-20260827_htm.xml
IDEA: XBRL DOCUMENT
0001776111
2026-08-27
2026-08-27
false
0001776111
8-K
2026-08-27
MBX Biosciences, Inc.
DE
001-42272
84-1882872
11711 N. Meridian Street
Suite 300
Carmel
IN
46032
(317)
659-0200
Not Applicable
false
false
false
false
Common Stock, $0.0001 par value per share
MBX
NASDAQ
true
false